Navigation Links
Sequential R-CHOP and Ibritumomab Tiuxetan (Zevalin(R)) Regimen Produces Impressive Survival Rates in High Risk Elderly Patients With Untreated Aggressive Diffuse Large B-cell Lymphoma
Date:6/8/2008

Oral presentation at international lymphoma conference shows investigational regimen resulted in 82 percent overall survival and 78

percent progression-free survival rates in patients receiving

radioimmunotherapy Confirmatory phase III clinical trial is presently being conducted in this

patient population

LUGANO, Switzerland, June 9 /PRNewswire-FirstCall/ -- In an oral presentation today at the 10th International Conference on Malignant Lymphoma in Lugano, Switzerland, Paul A. Hamlin, M.D., of Memorial Sloan-Kettering Cancer Center, presented results of an investigator-sponsored trial of the investigational regimen consolidating rituximab-CHOP (R-CHOP) with 90Yttrium Ibritumomab Tiuxetan (Zevalin(R)) radioimmunotherapy in high risk, elderly patients with previously untreated high-intermediate and high risk diffuse large B-cell lymphoma (DLBCL). Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) markets Zevalin in the United States.

"In a high risk, elderly patient population with significant comorbidities, sequential R-CHOP followed by radioimmunotherapy resulted in excellent complete response and overall and progression-free survival rates," concluded Hamlin. "This approach is now the focus of an international phase III study."

"Improvement of relapse-free survival in these patients is an important unmet need since the outcome is poor for patients who relapse with this disease and who cannot tolerate intensive salvage therapy and stem cell transplantation," said Jack W. Singer, M.D., Chief Medical Officer at CTI. "The survival data from this study are highly encouraging compared to historical data and provide the rationale for a registration-directed randomized trial of Zevalin consolidation in higher risk patients with DLBCL."

Results of the Study

Historical studies provided as background in the presentation indicate that approximately 50 perc
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. New Data Offers Insights Into the Potential Role for TYKERB(R) (Lapatinib) in Non-Cytotoxic Chemotherapy-Based Treatment Regimens
2. Perioperative Eloxatin(R)-Based Regimen Significantly Reduced the Risk of Relapse Versus Surgery Alone in Eligible Colorectal Cancer Patients with Initially Resectable Liver Metastases
3. European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection
4. Boehringer Ingelheim Initiates NEwArT Study Comparing Viramune(R) (nevirapine) to a Ritonavir-Boosted Atazanavir-based Regimen in Treatment-Naive HIV Patients
5. Studies Showing Significant Survival Improvement with Taxotere(R)-based Regimens in the Induction Treatment of Patients with Locally Advanced Head and Neck Cancer are Published in the Same Issue of the New England Journal of Medicine
6. Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV
7. New Phase III Data Presented for Once Monthly Dosing Regimen of Risedronate to Treat Postmenopausal Osteoporosis
8. New Study Shows Proprietary Canola Extract, Dermytol(TM), Produces Pronounced Decrease in Malignant Melanoma Tumor Volume
9. Fludarabine, Mitoxantrone and Zevalin(R) Produces 96% Complete Remission Rate in First-Line Treatment of Patients with Follicular Non-Hodgkins Lymphoma
10. Zevalin(R) Combined With High-Dose Chemotherapy and Autologous Stem-Cell Transplantation (ASCT) Produces High Overall Survival and Progression-Free Survival Rates in Patients With Relapsed Non-Hodgkins Lymphoma
11. VELCADE(R) (Bortezomib) for Injection Based Treatment Delivers Impressive Complete Response and Survival in Patients With Newly Diagnosed Multiple Myeloma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/30/2014)...  Boston Scientific has released the primary endpoint ... Failure (NECTAR-HF) clinical trial, the first and only ... (VNS) for the treatment of heart failure patients.  ... Cardiology and Director of the Clinical Investigation Center ... de la Recherche Medicale presented the results at ...
(Date:8/30/2014)... 2014   Royal Philips  (NYSE: PHG, AEX: PHIA) ... new ultrasound system designed to enable global hospitals and ... volumes and cost pressures. Making its debut at the  ... Barcelona this week, Affiniti provides innovative ... fewer resources deliver high quality patient care. ...
(Date:8/29/2014)... 2014 /PRNewswire-iReach/ -- Market Research Report on Global ... a professional and in-depth market survey on ... The report firstly reviews the basic information of ... manufacturing technology. The report then explores global and ... their product specification, capacity, Production value, and market ...
Breaking Medicine Technology:Boston Scientific Announces Primary Endpoint Results of NECTAR-HF Clinical Trial 2Boston Scientific Announces Primary Endpoint Results of NECTAR-HF Clinical Trial 3Boston Scientific Announces Primary Endpoint Results of NECTAR-HF Clinical Trial 4Philips Debuts New Affiniti Ultrasound System at the European Society of Cardiology Congress 2014 2Philips Debuts New Affiniti Ultrasound System at the European Society of Cardiology Congress 2014 3Philips Debuts New Affiniti Ultrasound System at the European Society of Cardiology Congress 2014 4X-Ray Crystallography Scanner Industry For Global and Chinese Market Forecast to 2019 2X-Ray Crystallography Scanner Industry For Global and Chinese Market Forecast to 2019 3X-Ray Crystallography Scanner Industry For Global and Chinese Market Forecast to 2019 4X-Ray Crystallography Scanner Industry For Global and Chinese Market Forecast to 2019 5
... - Inovio Biomedical,Corporation (AMEX:INO), focused on the ... diseases and a novel alternative to,surgery to ... partner, Vical Incorporated, presented positive interim,safety and ... ongoing Phase I,clinical trial using Inovio's electroporation ...
... Clinical results from a,Phase II study presented ... Society (AHS) annual meeting showed that MK-0974, ... significantly improved migraine pain relief,two hours after ... was,sustained through 24 hours. MK-0974 was generally ...
Cached Medicine Technology:Vical Interim Clinical Results Demonstrate Safety and Tolerability,of Inovio Biomedical's Electroporation DNA Delivery Technology 2Vical Interim Clinical Results Demonstrate Safety and Tolerability,of Inovio Biomedical's Electroporation DNA Delivery Technology 3Vical Interim Clinical Results Demonstrate Safety and Tolerability,of Inovio Biomedical's Electroporation DNA Delivery Technology 4Vical Interim Clinical Results Demonstrate Safety and Tolerability,of Inovio Biomedical's Electroporation DNA Delivery Technology 5Merck's Investigational Migraine Treatment MK-0974 Significantly,Improved Migraine Pain on Several Efficacy Measures in a Phase II,Study 2Merck's Investigational Migraine Treatment MK-0974 Significantly,Improved Migraine Pain on Several Efficacy Measures in a Phase II,Study 3Merck's Investigational Migraine Treatment MK-0974 Significantly,Improved Migraine Pain on Several Efficacy Measures in a Phase II,Study 4Merck's Investigational Migraine Treatment MK-0974 Significantly,Improved Migraine Pain on Several Efficacy Measures in a Phase II,Study 5
(Date:8/30/2014)... United Theological Seminary is pleased to announce ... Master of Theological Studies (MTS). , This ... for students who wish to pursue further academic study of ... serve the Church and community. Previously, students needed to be ... attend classes from any location where there is an internet ...
(Date:8/30/2014)... 30, 2014 Hands On ... which offers the complete spa experience combining elegant ... and the most important ingredient of all, states ... licensed pro's! People will enjoy the get-away feel, ... The website reads, "Step into the spacious, luxurious ...
(Date:8/30/2014)... 2014 Patients suffering from vitiligo can ... a new review published by Daily Gossip. , ... so there is no wonder that numerous sufferers search ... Vitiligo Treatment is one of the most appreciated such ... promises to stop the spread of this disorder immediately, ...
(Date:8/30/2014)... Daily Gossip reveals in its review a program created ... who shows a unique formula to get inside a man’s ... that the program goes beyond mere attraction and actually helps ... indicates that the program was created by dating expert Alex ... to make a man feel emotionally addicted. , Learn more ...
(Date:8/30/2014)... (PRWEB) August 30, 2014 Daily Gossip ... that keeps anxiety and panic attacks under control with ... Away" program review describes this new method as ... control panic attacks and overcome general anxiety related disorders. ... successful is the fact that it can be accessed ...
Breaking Medicine News(10 mins):Health News:United Theological Seminary Announces First Fully Online Degree 2Health News:Hands On Mobile Massage and Spa of Long Island Now Offers a Spa-on-wheels 2Health News:Natural Vitiligo Treatment Review Exposes Fast Method for Skin Repigmentation 2Health News:Make Him Desire You Review Reveals Powerful Formula to Make a Man Emotionally Addicted 2Health News:Panic Away Review Reveals New Natural Remedy for Anxiety Patients 2
... Solutions for Medical Equipment, Building Infrastructure and Automation, ... NEW YORK, March 23 Via Christi Health ... a wide range of technology and service solutions ... Christi Health System,s strategic plan.(Logo: http://www.newscom.com/cgi-bin/prnh/20070904/SIEMENSLOGO ...
... Siemens Financial Services, Inc. announced today that ... to El Camino Hospital in Mountain View, California. ... a variety of Siemens Medical Solutions equipment which ... hospital under construction.(Logo: http://www.newscom.com/cgi-bin/prnh/20070904/SIEMENSLOGO )"For more ...
... Education Virtual Lecture for Healthcare ProfessionalsVOORHEES, N.J., March ... infection (CDI) is changing rapidly and has ... and severity. Management of CDI can be challenging ... updated. In order to effectively implement key strategies ...
... WASHINGTON, March 23 March 22 was World Water ... of the 1992 United Nations Conference on Environment and ... of World Water Day this year is Transboundary Waters: ... the Poor Act of 2005 makes access to safe ...
... MBF Healthwatch survey has revealed that a disturbing number of ... they are ,too tired, or ,can,t be bothered, having a ... 22% of parents interviewed said their children skip breakfast on ... further 20% skip breakfast on one or two school days. ...
... get relief from their symptoms and the psychological distress ... , Skin experts and psychologists at The University of ... known as ,electronic Targeted Intervention for Psoriasis, or eTIPS ... better. , "Psoriasis is a skin disease that usually ...
Cached Medicine News:Health News:Via Christi Health System and Siemens Announce Technology Alliance 2Health News:Siemens Financial Services, Inc. Announces Completion of Tax-Exempt Financing With El Camino Hospital 2Health News:Siemens Financial Services, Inc. Announces Completion of Tax-Exempt Financing With El Camino Hospital 3Health News:Clostridium difficile Infection in Primary Care: Tackling a Virulent Pathogen 2Health News:USAID World Water Day Statement 2Health News:USAID World Water Day Statement 3Health News:School kids 'wagging' breakfast are missing healthy brain fuel 2Health News:Experts turn to Web to combat distressing skin disease 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: